Interpace Biosciences, Inc. announced that Thomas Freeburg, the Chief Financial Officer resigned from his position as Chief Financial Officer and as an employee of the Company. Pursuant to a Severance and Consulting Agreement and General Release between the Company and Mr. Freeburg (the Consulting Agreement) effective September 30, 2022, Mr. Freeburg will provide certain consulting services to the Company, including finance and accounting services, as requested or deemed appropriate by the Company's Chief Executive Officer and/or other senior management employees. Mr. Freeburg will continue to act as the Company's principal financial officer during the Consulting Term, until such time as the Company recruits a new Chief Financial Officer to replace Mr. Freeburg.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | +2.16% | -3.24% | +31.48% |
Mar. 07 | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M | MT |
Mar. 07 | Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+31.48% | 6.07M | |
-15.28% | 5.6B | |
+3.61% | 1.29B |
- Stock Market
- Equities
- IDXG Stock
- News Interpace Biosciences, Inc.
- Interpace Biosciences, Inc. Announces Resignation of Thomas Freeburg as Chief Financial Officer